

Rossella Elisei

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4949400/rossella-elisei-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330
papers

21,517
citations

69
h-index

142
g-index

354
ext. papers

25,082
ext. citations

5.3
avg, IF

6.4
L-index

#	Paper	IF	Citations
330	2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. <i>European Thyroid Journal</i> , 2022 , 11,	4.2	5
329	Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 864253	5.7	1
328	Clinical-Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 842424	5.7	1
327	Bilateral testicular metastases of MTC in an adult male with MEN2A syndrome: case report and review of literature.. <i>European Thyroid Journal</i> , 2022 ,	4.2	
326	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors 2022 , 1-40		
325	Radionuclide Therapy of Thyroid Tumors 2022 , 1-50		
324	Carcinoma differenziato della tiroide radioiodio-refrattario in progressione trattato con lenvatinib. <i>L Endocrinologo</i> , 2021 , 22, 570	0	
323	La gestione multidisciplinare delle metastasi ossee nel carcinoma tiroideo. <i>L Endocrinologo</i> , 2021 , 22, 497	0	
322	Esami diagnostici nel sospetto di carcinoma midollare della tiroide. <i>L Endocrinologo</i> , 2021 , 22, 454	0	
321	A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy 2021 , 337-346		
320	Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases 2021 , 327-335		
319	Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	13
318	[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2355-2366	5.6	1
317	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. <i>Thyroid</i> , 2021 , 31, 1226-1234	6.3	6
316	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab093	0.4	1
315	Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4109-e4117	5.6	1
314	I tempi della tiroidectomia nella MEN2. <i>L Endocrinologo</i> , 2021 , 22, 59-61	0	

313	Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs. <i>Cancers</i> , 2021 , 13,	6.6	2
312	Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4072-e4083	5.6	3
311	Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution. <i>Cancers</i> , 2021 , 13,	6.6	5
310	Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2557-2566	5.2	3
309	Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103366	7	2
308	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 3228-3238	5.6	8
307	Proteinuria is a late-onset adverse event in patients treated with cabozantinib. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 95-103	5.2	8
306	Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo. <i>Thyroid</i> , 2021 , 31, 330-331	6.2	0
305	First report of benign track seeding after robot-assisted transaxillary thyroid surgery. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021 , 42, 102811	2.8	2
304	Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. <i>Thyroid</i> , 2021 , 31, 1050-1055	6.2	4
303	Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System. <i>Thyroid</i> , 2021 , 31, 1056-1066	6.2	1
302	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. <i>Thyroid</i> , 2021 , 31, 224-232	6.2	15
301	Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma. <i>Endocrine</i> , 2021 , 72, 140-146	4	2
300	Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	6
299	Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium. <i>International Journal of Cancer</i> , 2021 , 148, 2935-2946	7.5	5
298	RET mutated C-cells proliferate more rapidly than non-mutated neoplastic cells. <i>Endocrine Connections</i> , 2021 , 10, 124-130	3.5	0
297	A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	13
296	Thyroid cancer and COVID-19: experience at one single thyroid disease referral center. <i>Endocrine</i> , 2021 , 72, 332-339	4	5

295	Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2139-2151	5.2	5
294	MANAGEMENT OF ENDOCRINE DISEASE: Papillary thyroid microcarcinoma: toward an active surveillance strategy. <i>European Journal of Endocrinology</i> , 2021 , 185, R23-R34	6.5	3
293	Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report. <i>Annals of Oncology</i> , 2021 , 32, 1447-1449	10.3	6
292	Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2021 , 185, 193-200	6.5	8
291	Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
290	Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2021 , 10, 399-407	4.2	1
289	Letter to the Editor-ResponseResponse to Letter to the Editor: "Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	
288	Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
287	Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up. <i>Endocrine</i> , 2020 , 68, 607-616	4	6
286	Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. <i>Frontiers in Endocrinology</i> , 2020 , 11, 381	5.7	5
285	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2773-2781	2.2	18
284	Eterogeneità genetica del carcinoma tiroideo. <i>L Endocrinologo</i> , 2020 , 21, 48-50	0	
283	Polymorphisms Within the Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2020 , 30, 1579-1588	6.2	0
282	Firm mass in thyroid of an elderly patient: not always cancer. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020 , 2020,	1.4	1
281	Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. <i>Endocrine-Related Cancer</i> , 2020 , 27, 97-110	5.7	19
280	Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma. <i>Cancers</i> , 2020 , 13,	6.6	4
279	Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases. <i>Endocrine Practice</i> , 2020 , 26, 807-817	3.2	3
278	MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78

277	MON-486 Polygenic Susceptibility to Papillary Thyroid Cancer in Italian Subjects. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
276	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	43
275	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. <i>European Journal of Cancer</i> , 2020 , 124, 161-169	7.5	24
274	Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	13
273	1927TIP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC). <i>Annals of Oncology</i> , 2020 , 31, S1091	10.3	2
272	Qualità della vita nei pazienti con microcarcinoma papillare della tiroide in funzione del trattamento: tiroidectomia totale con o senza terapia radiometabolica ablativa. <i>L Endocrinologo</i> , 2020 , 21, 397-398	0	
271	A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New Germline Deletion. <i>Case Reports in Endocrinology</i> , 2020 , 2020, 4147097	1.2	0
270	DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER. <i>Endocrine Practice</i> , 2020 , 26, 58-71	3.2	5
269	Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 109-116	5.2	10
268	Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review. <i>Minerva Endocrinologica</i> , 2020 , 45, 306-317	1.9	4
267	Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?. <i>International Journal of Cancer</i> , 2020 , 147, 2838-2846	7.5	6
266	Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. <i>Endocrine-Related Cancer</i> , 2020 , 27, 97-110	5.7	8
265	Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. <i>Genes</i> , 2019 , 10,	4.2	22
264	2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2019 , 8, 227-245	4.2	90
263	Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. <i>IScience</i> , 2019 , 20, 324-336	6.1	48
262	Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer. <i>Case Reports in Endocrinology</i> , 2019 , 2019, 6831237	1.2	2
261	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2520-2526	5.6	11
260	Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. <i>Annales D'Endocrinologie</i> , 2019 , 80, 187-190	1.7	6

259 Medullary Thyroid Cancer **2019**, 673-691

258 Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. *European Journal of Cancer*, **2019**, 118, 35-40 7.5 48

257 Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas. *Endocrine*, **2019**, 65, 623-629 4 0

256 Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. *Cancers*, **2019**, 11, 6.6 6

255 Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. *Endocrine-Related Cancer*, **2019**, 26, 241-250 5.7 12

254 somatic mutations strongly impair miRNA processing even in benign thyroid lesions. *Oncotarget*, **2019**, 10, 1785-1797 3.3 12

253 The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. *Frontiers in Oncology*, **2019**, 9, 1390 5.3 3

252 Management of Medullary Thyroid Cancer. *Endocrinology and Metabolism Clinics of North America*, **2019**, 48, 285-301 5.5 32

251 European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. *Thyroid*, **2019**, 29, 7-26 6.2 59

250 Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. *Lancet Diabetes and Endocrinology*, **2019**, 7, 213-220 18.1 52

249 Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan. *European Thyroid Journal*, **2019**, 8, 90-95 4.2 5

248 mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. *Journal of Endocrinological Investigation*, **2018**, 41, 1389-1399 5.2 12

247 BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. *Journal of the National Cancer Institute*, **2018**, 110, 362-370 9.7 42

246 Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. *Head and Neck*, **2018**, 40, 1752-1758 4.2 15

245 Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients. *Journal of Endocrinological Investigation*, **2018**, 41, 357-361 5.2 4

244 SP134PROTEINURIA IS A LATE ONSET ADVERSE EVENT IN PATIENTS TREATED WITH CABOZANTINIB: A SINGLE CENTER EXPERIENCE. *Nephrology Dialysis Transplantation*, **2018**, 33, i388-i389 4.3 1

243 The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans. *Archives of Toxicology*, **2018**, 92, 2137-2140 5.8 4

242 Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. *Journal of Endocrinological Investigation*, **2018**, 41, 849-876 5.2 95

241	Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. <i>Thyroid</i> , 2018 , 28, 1318-1324	6.2	2
240	A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. <i>Molecular and Clinical Oncology</i> , 2018 , 8, 449-452	1.6	
239	Medullary Carcinoma. <i>Endocrinology</i> , 2018 , 1-39	0.1	
238	Thyroid Carcinoma 2018 , 573-585		2
237	Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 438-445	2.2	68
236	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2787-2795	2.2	38
235	Medullary Thyroid Cancer: Diagnosis and Non Surgical Management 2018 , 223-239		
234	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. <i>Frontiers in Endocrinology</i> , 2018 , 9, 590	5.7	3
233	RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. <i>Oncotarget</i> , 2018 , 9, 9875-9884	3.3	16
232	Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. <i>Oncology Letters</i> , 2018 , 15, 9174-9182	2.6	14
231	Medullary Carcinoma. <i>Endocrinology</i> , 2018 , 589-627	0.1	
230	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without I Ablation. <i>Thyroid</i> , 2018 , 28, 871-879	6.2	21
229	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017 , 75, 213-221	7.5	39
228	Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 207-214	4.1	
227	Clancora indicazione alla terapia radioablativa con 131-I nel carcinoma tiroideo differenziato a basso rischio?. <i>L Endocrinologo</i> , 2017 , 18, 51-53	0	
226	Response to Letter: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1785-1786	5.6	1
225	Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017 , 31, 319-334	6.5	22
224	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3241-3250	5.6	55

223	Targeted Therapy in Thyroid Cancer: State of the Art. <i>Clinical Oncology</i> , 2017 , 29, 316-324	2.8	74
222	Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations. <i>Journal of Surgical Oncology</i> , 2017 , 116, 1197-1199	2.8	3
221	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Annals of Oncology</i> , 2017 , 28, 2813-2819	10.3	101
220	Comunicare con la persona con cancro della tiroide in progressione. <i>L Endocrinologo</i> , 2017 , 18, 224-230	0	1
219	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. <i>Nature Reviews Endocrinology</i> , 2017 , 13, 644-660	15.2	208
218	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3091-3096	5.6	2
217	Role of YAP-1 in Thyroid Tumor Progression and Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017 , 25, 581-585	1.9	7
216	Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. <i>Thyroid</i> , 2017 , 27, 1267-1276	6.2	25
215	Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 55-62	5.2	17
214	Inherited variants in genes somatically mutated in thyroid cancer. <i>PLoS ONE</i> , 2017 , 12, e0174995	3.7	4
213	Calcitonin receptor expression in medullary thyroid carcinoma. <i>PeerJ</i> , 2017 , 5, e3778	3.1	2
212	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors 2017 , 545-583		1
211	Radionuclide Therapy of Thyroid Tumors 2017 , 1197-1241		0
210	Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 893-902	5.6	27
209	Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 341-7	5.2	25
208	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 44-53	12.9	152
207	Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. <i>Cancer</i> , 2016 , 122, 3856-3864	6.4	58
206	Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4413-4420	5.6	38

205	A Comparison of the ATA, NCCN, ETA, and BTA Guidelines for the Management of Medullary Thyroid Cancer 2016 , 899-910		1
204	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2016 , 5, 187-194	4.2	10
203	Alterazioni genomiche e trascrittomiche che caratterizzano il carcinoma scarsamente differenziato e anaplastico della tiroide. <i>L Endocrinologo</i> , 2016 , 17, 176-177	0	
202	Influenza dell'avanzare dell'età sulla formazione dei noduli tiroidei, sull'evoluzione multinodulare e sul rischio neoplastico. <i>L Endocrinologo</i> , 2016 , 17, 62-63	0	
201	Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. <i>Archives of Toxicology</i> , 2016 , 90, 3099-3109	5.8	5
200	A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy 2016 , 355-363		
199	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 264-74	5.6	144
198	Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases 2016 , 347-354		2
197	A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. <i>Nature Reviews Endocrinology</i> , 2016 , 12, 192-202	15.2	173
196	A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 700-13	4	16
195	Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age. <i>Current Pediatric Reviews</i> , 2016 , 12, 280-285	2.8	7
194	Radionuclide Therapy of Thyroid Tumors 2016 , 1-47		
193	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors 2016 , 1-40		1
192	Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. <i>OncoTargets and Therapy</i> , 2016 , 9, 6467-6477	4.4	29
191	New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double mutations. <i>Journal of Medical Genetics</i> , 2016 , 53, 729-734	5.8	38
190	Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato. <i>L Endocrinologo</i> , 2016 , 17, 266-267	0	
189	Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. <i>Endocrine-Related Cancer</i> , 2016 , 23, R185-205	5.7	119
188	Reply to the Letter to the Editor by Sollini M et al. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 487-8	5.2	2

187	Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. <i>DNA Repair</i> , 2016 , 41, 27-31	4.3	5
186	Runs of homozygosity and inbreeding in thyroid cancer. <i>BMC Cancer</i> , 2016 , 16, 227	4.8	15
185	Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1316-24	5.6	167
184	Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. <i>European Journal of Endocrinology</i> , 2015 , 173, 297-304	6.5	23
183	Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. <i>Thyroid</i> , 2015 , 25, 567-610	6.2	1191
182	Effects of radioiodine treatment for differentiated thyroid cancer on testis function. <i>Clinical Endocrinology</i> , 2015 , 82, 295-9	3.4	12
181	Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?. <i>Clinical Endocrinology</i> , 2015 , 82, 892-9	3.4	41
180	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 42-50	2.2	345
179	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015 , 38, 193-259	5.2	9
178	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. <i>Cancer</i> , 2015 , 121, 2749-56	6.4	130
177	Impatto dell'analisi di sequenza multigenica avanzata Thyroseq sulla diagnosi di cancro nei noduli tiroidei con atipie di incerto significato e/o lesioni follicolari a citologia indeterminata. <i>L Endocrinologo</i> , 2015 , 16, 237-238	0	
176	Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. <i>Scientific Reports</i> , 2015 , 5, 8922	4.9	21
175	Cabozantinib: an orphan drug for thyroid cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 1469-1477	1.1	1
174	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4387-95	5.6	11
173	Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 621-30	59.2	1078
172	Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6012-6012	2.2	20
171	Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6013-6013	2.2	3
170	Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6014-6014	2.2	2

169	Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6015-6015	2.2	2
168	Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6048-6048	2.2	7
167	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2014 , 384, 319-28	4.0	933
166	Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. <i>European Journal of Endocrinology</i> , 2014 , 171, R33-46	6.5	72
165	Il carcinoma tiroideo: nuove prospettive terapeutiche. <i>L Endocrinologo</i> , 2014 , 15, 28-35	0	
164	How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 331-44	5.5	14
163	Clinical case seminar in pediatric thyroid disease. <i>Endocrine Development</i> , 2014 , 26, 214-44		1
162	Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2084-92	5.6	35
161	Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. <i>Thyroid</i> , 2014 , 24, 966-74	6.2	69
160	Medullary thyroid carcinoma in children. <i>Endocrine Development</i> , 2014 , 26, 202-13		9
159	FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment. <i>Thyroid</i> , 2014 , 24, 339-46	6.2	15
158	Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic ¹³¹ I whole-body scan and detectable serum thyroglobulin levels. <i>Journal of Endocrinological Investigation</i> , 2014 , 7, 247-50	5.2	5
157	Randomized safety and efficacy study of foscetabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. <i>Thyroid</i> , 2014 , 24, 232-40	6.2	108
156	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6060-6060	2.2	11
155	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6061-6061	2.2	6
154	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA6008-LBA6008	2.2	6
153	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA6008-LBA6008	2.2	16
152	Incidental versus clinically evident thyroid cancer: a 5-year follow-up study. <i>Head and Neck</i> , 2013 , 35, 408-12	4.2	5

151	Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. <i>Thyroid Research</i> , 2013 , 6 Suppl 1, S2	2.4	19
150	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1493-501	27.4	605
149	Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. <i>Mutation Research - Reviews in Mutation Research</i> , 2013 , 752, 36-44	7	56
148	Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 2121-5	4	7
147	Genome-wide association study on differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1674-81	5.6	64
146	Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. <i>Thyroid</i> , 2013 , 23, 1211-25	6.2	120
145	Thyroid and Parathyroid Tumors 2013 , 297-361		
144	2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. <i>European Thyroid Journal</i> , 2013 , 1, 216-31	4.2	66
143	Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. <i>Thyroid</i> , 2013 , 23, 50-7	6.2	126
142	Cabozantinib in progressive medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3639-46	2.2	762
141	Nuove indicazioni all'impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. <i>L Endocrinologo</i> , 2013 , 14, 255-260	0	
140	Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3550-4	5.6	20
139	TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. <i>International Journal of Cancer</i> , 2013 , 133, 2843-51	7.5	14
138	Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹ I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2693-700	5.6	48
137	Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. <i>Future Oncology</i> , 2013 , 9, 1083-92	3.6	68
136	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4-4	2.2	14
135	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4-4	2.2	39
134	Follicular-derived neoplasms: morphometric and genetic differences. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 1055-61	5.2	7

133	Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapeutic effect of vinorelbine in the medullary thyroid cancer TT cell line. <i>Molecular and Cellular Endocrinology</i> , 2012 , 355, 41-8	4.4	14
132	Advances in the follow-up of differentiated or medullary thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2012 , 8, 466-75	15.2	62
131	Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2012 , 348, 176-82	4.4	15
130	Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. <i>Thyroid</i> , 2012 , 22, 476-81	6.2	49
129	Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. <i>Surgery</i> , 2012 , 152, 1078-87	3.6	37
128	Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1137-47	3.5	41
127	Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. <i>Journal of Oncology</i> , 2012 , 2012, 705036	4.5	55
126	RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2012 , 3, 54	5.7	99
125	Reply to J.-F. Chatal et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2166-2167	2.2	
124	The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 4390-8	5.6	175
123	Modifications in the papillary thyroid cancer gene profile over the last 15 years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E1758-65	5.6	59
122	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 134-41	2.2	1000
121	The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 426-35	5.6	96
120	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5508-5508	2.2	54
119	A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5591-5591	2.2	20
118	New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 3-9	5.2	29
117	RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). <i>Clinical Endocrinology</i> , 2011 , 74, 241-7	3.4	82
116	Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. <i>International Journal of Cancer</i> , 2011 , 129, 2816-24	7.5	26

115	Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. <i>Thyroid</i> , 2011 , 21, 1209-15	6.2	28
114	CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2011 , 164, 397-404	6.5	25
113	In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2011 , 18, 603-12	5.7	49
112	A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 5502-5502	2.2	19
111	A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 5503-5503	2.2	55
110	Carcinoma della tiroide 2011 , 403-420		
109	Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 4197-205	5.6	139
108	Acute exogenous TSH administration stimulates leptin secretion in vivo. <i>European Journal of Endocrinology</i> , 2010 , 163, 63-7	6.5	46
107	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010 , 163, 301-8	6.5	95
106	Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1516-27	5.6	167
105	Correlazione genotipo-fenotipo nelle MEN 2: stato dell'arte dopo 15 anni di conoscenze. <i>L'Endocrinologo</i> , 2010 , 11, 94-101	0	
104	Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 579-86	5.2	7
103	Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. <i>Journal of Pediatric Surgery</i> , 2010 , 45, 1610-6	2.6	15
102	Ethics in Robotic Surgery and Telemedicine 2010 , 457-465		1
101	Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. <i>Endocrine-Related Cancer</i> , 2009 , 16, 1251-60	5.7	163
100	Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3794-801	2.2	293
99	Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4171-9	5.6	69
98	A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. <i>Thyroid</i> , 2009 , 19, 837-42	6.2	71

97	Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. <i>Molecular and Cellular Endocrinology</i> , 2009 , 307, 142-8	4.4	35
96	Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1618-22	5.6	73
95	Thyroid Cancer in Ukraine After the Chernobyl Accident: Incidence, Pathology, Treatment, and Molecular Biology 2009 , 305-316		2
94	Routine serum calcitonin measurement in the evaluation of thyroid nodules. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 941-53	6.5	62
93	Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. <i>Molecular and Cellular Endocrinology</i> , 2008 , 291, 57-62	4.4	47
92	Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 724-30	5.2	14
91	Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 682-7	5.6	395
90	BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008 , 15, 511-20	5.7	120
89	Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2729-36	5.6	37
88	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3943-9	5.6	416
87	Anaplastic thyroid cancer: prevalence, diagnosis and treatment. <i>Minerva Endocrinologica</i> , 2008 , 33, 341-57		68
86	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2007 , 54, 390.e1-390.e16		
85	The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3511-6	5.6	82
84	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4085-90	5.6	329
83	Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007 , 21, 120-3	5.2	48
82	RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4725-9	5.6	203
81	Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2007 , 14, 1099-105	5.7	46
80	Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. <i>Human Pathology</i> , 2007 , 38, 1482-8	3.7	18

79	Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. <i>Thyroid</i> , 2007 , 17, 389-93	6.2	62
78	Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. <i>Thyroid</i> , 2007 , 17, 381-8	6.2	58
77	Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients. <i>Clinical Endocrinology</i> , 2007 , 66, 13-20	3.4	82
76	Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. <i>Endocrine-Related Cancer</i> , 2006 , 13, 455-64	5.7	184
75	Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2389-95	5.6	34
74	Medullary Thyroid Cancer: Diagnosis and Management 2006 , 255-279		3
73	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. <i>European Journal of Endocrinology</i> , 2006 , 154, 787-803	6.5	1487
72	Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 926-32	5.6	337
71	Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2006 , 29, 131-5	5.2	23
70	Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 124-7	5.6	155
69	Tiroidectomia profilattica nelle neoplasie endocrine multiple di tipo 2A. <i>L Endocrinologo</i> , 2005 , 6, 200-204		
68	All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2403-11	5.6	37
67	Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4047-50	5.6	24
66	RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. <i>Thyroid</i> , 2005 , 15, 1355-61	6.2	19
65	A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4810-6	5.6	12
64	Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. <i>Thyroid</i> , 2004 , 14, 946-52	6.2	49
63	RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3579-84	5.6	97
62	Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. <i>Journal of Endocrinology</i> , 2004 , 182, 479-84	4.7	14

61	Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 33-9	5.6	45
60	Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 163-8	5.6	389
59	Diagnosi genetica del carcinoma midollare della tiroide: implicazioni diagnostiche e terapeutiche. <i>L Endocrinologo</i> , 2004 , 5, 39-46	0	
58	Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 866-9	5.2	6
57	Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 557-61	5.2	24
56	Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 636-42	5.2	1
55	BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2414-20	5.6	235
54	Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5823-7	5.6	54
53	Authors' Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules? Will the Law Answer before Endocrinologists Do?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4770-4770	5.6	
52	Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. <i>European Journal of Endocrinology</i> , 2003 , 148, 579-86	6.5	12
51	Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 748-54	5.6	55
50	Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 892-9	5.6	26
49	Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. <i>Clinical Endocrinology</i> , 2003 , 59, 500-6	3.4	19
48	Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3668-73	5.6	319
47	Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. <i>Thyroid</i> , 2003 , 13, 765-70	6.2	45
46	Biology and clinical application of the NIS gene. <i>Tumori</i> , 2003 , 89, 523-8	1.7	2
45	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. <i>International Journal of Cancer</i> , 2002 , 97, 608-14	7.5	37
44	Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 4160-5	5.6	80

43	Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1499-501	5.6	223
42	Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 4063-8	5.6	145
41	Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. <i>American Journal of Pathology</i> , 2002 , 160, 247-54	5.8	89
40	Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. <i>Surgery</i> , 2002 , 132, 1070-3; discussion 1073-4	3.6	170
39	RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2001 , 145, 599-604	6.5	38
38	RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 3211-6	5.6	192
37	Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 4092-7	5.6	194
36	Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5686-90	5.6	142
35	Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. <i>Thyroid</i> , 2001 , 11, 877-81	6.2	118
34	Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2001 , 24, 445-7	5.2	8
33	RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 3211-3216	5.6	164
32	New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2000 , 53, 131-6	3.4	15
31	N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. <i>Thyroid</i> , 2000 , 10, 19-23	6.2	136
30	Conditional apoptosis induced by oncogenic ras in thyroid cells. <i>Molecular Endocrinology</i> , 2000 , 14, 1725-38		48
29	RET proto-oncogene mutations in thyroid carcinomas: clinical relevance. <i>Journal of Endocrinological Investigation</i> , 2000 , 23, 328-38	5.2	25
28	Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. <i>Journal of Biological Chemistry</i> , 1999 , 274, 23414-25	5.4	57
27	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998 , 83, 2185-2193	6.4	59
26	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas 1998 , 83, 2185		3

25	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998 , 83, 2185-93	6.4	14
24	Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets. <i>Nucleic Acids Research</i> , 1997 , 25, 3823-31	20.1	35
23	Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT). <i>Journal of Endocrinological Investigation</i> , 1996 , 19, 230-5	5.2	3
22	Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 1619-22	5.6	122
21	Post-surgical follow-up of differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 1995 , 18, 165-6	5.2	8
20	Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. <i>Surgery</i> , 1995 , 118, 1031-5	3.6	63
19	T cell responses to orbital antigens in thyroid-associated ophthalmopathy. <i>Clinical and Experimental Immunology</i> , 1994 , 96, 329-34	6.2	21
18	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 78, 867-71	5.6	50
17	Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. <i>European Journal of Cancer</i> , 1994 , 30A, 171-4	7.5	30
16	Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 78, 826-9	5.6	184
15	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 78, 867-871	5.6	45
14	Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993 , 76, 499-503	5.6	76
13	Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. <i>Journal of Endocrinological Investigation</i> , 1993 , 16, 329-32	5.2	32
12	Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. <i>Journal of Endocrinological Investigation</i> , 1993 , 16, 511-9	5.2	40
11	Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. <i>Journal of Endocrinological Investigation</i> , 1993 , 16, 533-40	5.2	15
10	Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992 , 74, 1401-4	5.6	170
9	Expression of calcitonin gene-related peptide in medullary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 1992 , 15, 539-42	5.2	8
8	Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. <i>American Journal of Clinical Pathology</i> , 1991 , 95, 300-8	1.9	73

7	Demonstration of the existence of the alternatively spliced form of thyroid peroxidase in normal thyroid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 700-2	5.6	21
6	Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. <i>Autoimmunity</i> , 1990 , 8, 65-70	3	25
5	Somatostatin in medullary thyroid cancer. In vitro and in vivo studies. <i>Cancer</i> , 1989 , 63, 1189-95	6.4	42
4	Thyroid carcinoma in thyrotoxic patients treated by surgery. <i>Journal of Endocrinological Investigation</i> , 1988 , 11, 107-12	5.2	99
3	Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. <i>European Journal of Endocrinology</i> , 1988 , 119, 373-80	6.5	112
2	Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. <i>Journal of Nuclear Medicine</i> , 1987 , 28, 1888-91	8.9	159
1	Nuovi farmaci inibitori selettivi di RET (selpercatinib e pralsetinib) nei pazienti con carcinoma midollare della tiroide avanzato. <i>L'Endocrinologo</i> , 1	0	